The Impact of Impurity Analysis on Future Regulations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Impact of Impurity Analysis on Future Regulations
As technology for impurity analysis improves, scientists are gaining better information and asking for more regulatory guidance.


Pharmaceutical Technology


References

1. N. Rao and V. Nagaraju, "An Overview of the Recent Trends in Development of HPLC Methods for Determination of Impurities in Drugs," J. Pharm. Biomed. Anal. 33, 335–377 (2003).

2. D. Elder, "To Boldly Go Where No Analyst Has Gone Before? New Technologies in Characterization and Control of Impurites" presented at the USP Annual Scientific Meeting, Denver, CO, Sept. 28, 2006.

3. Q. Wang et al., "A General Overview of Emerging Technologies for Pharmaceutical Impurity Detection and Characterization," presented at the USP Annual Scientific Meeting, Denver, CO, Sept. 28, 2006.

4. Müller et al., "A Rationale for Determining, Testing, and Controlling Specific Impurities in Pharmaceuticals that Possess Potential for Genotoxicity," Reg. Tox. Pharm. 44, 198–211 (2006).

5. R.W. Dugger, J.A. Ragan, and D.H. Brown, "Survey of GMP Bulk Reactions Run in a Research Facility Between 1985 and 2002," Org. Proc. Res. Dev. 9, 253–238 (2005).

6. J.S. Carey et. al, "Analysis of the Reactions Used for the Preparation of Drug Candidate Molecules," Org. Biomol. Chem. 4, 2337–2347 (2006). PT


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
20%
Protecting the supply chain
50%
Expedited reviews of drug submissions
0%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here